EXECUTIVE INSIGHTS
DOMAIN EXPERTS
PLAYERS
PARTICIPANTS
-
FEB 2025
-
EDITION 2
-
TABLES 210
-
REGIONS 26
-
SEGMENTS 7
-
PAGES 289
-
US$ 5600
-
MCP26617
-
JOIN OUR PANEL
EXECUTIVE ENGAGEMENTS BY TIER
-
CXO
-
VICE PRESIDENT
-
DIRECTOR
-
MANAGER
-
MARKETING
HIGHLIGHTS & REPORT INDEX
Global Neurologic Disorders Therapeutics Market to Reach US$149.7 Billion by 2030
The global market for Neurologic Disorders Therapeutics estimated at US$121.2 Billion in the year 2024, is expected to reach US$149.7 Billion by 2030, growing at a CAGR of 3.6% over the analysis period 2024-2030. Anticholinergic Drug Class, one of the segments analyzed in the report, is expected to record a 3.9% CAGR and reach US$45.2 Billion by the end of the analysis period. Growth in the Analgesics Drug Class segment is estimated at 4.3% CAGR over the analysis period.
The U.S. Market is Estimated at US$32.7 Billion While China is Forecast to Grow at 6.9% CAGR
The Neurologic Disorders Therapeutics market in the U.S. is estimated at US$32.7 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$31.3 Billion by the year 2030 trailing a CAGR of 6.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.1% and 2.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.9% CAGR.
Global Neurologic Disorders Therapeutics Market - Key Drivers and Trends Summarized
Neurologic disorders encompass a broad range of conditions that affect the nervous system, including the brain, spinal cord, and peripheral nerves. These disorders can be debilitating and include diseases such as Alzheimer`s, Parkinson`s, multiple sclerosis, epilepsy, and stroke, among others. The therapeutic approaches for neurologic disorders vary widely depending on the specific condition, but generally aim to manage symptoms, slow disease progression, and improve the quality of life for patients. Treatments can include medications, physical and occupational therapy, lifestyle changes, and, in some cases, surgical interventions.
The field of neurologic disorder therapeutics has seen significant advancements over the past few decades. The development of disease-modifying therapies has transformed the management of conditions like multiple sclerosis and Parkinson`s disease, offering patients options that go beyond symptomatic relief. For instance, the introduction of monoclonal antibodies and other biologic drugs has provided new avenues for targeting the underlying pathophysiology of these diseases. Advances in neuroimaging and biomarker research have also enhanced early diagnosis and personalized treatment plans. Moreover, innovative drug delivery systems, such as intrathecal pumps and transdermal patches, have improved the efficacy and convenience of administering neurologic medications.
The growth in the neurologic disorders therapeutics market is driven by several factors. Firstly, the increasing prevalence of neurologic conditions, particularly among aging populations, has heightened the demand for effective treatments. Secondly, advancements in biotechnology and pharmaceutical research are continuously leading to the development of new and improved therapies, including gene therapies and neuroprotective agents. The expansion of healthcare infrastructure in emerging markets has also facilitated better access to neurologic care, contributing to market growth. Additionally, strategic collaborations between pharmaceutical companies, academic institutions, and research organizations are accelerating the discovery and commercialization of innovative treatments. The rise of digital health technologies, including telemedicine and wearable devices, is enhancing patient monitoring and management, leading to better outcomes. Lastly, increased funding for neurologic research and the development of comprehensive treatment guidelines are fostering a more structured and effective approach to managing neurologic disorders.
SCOPE OF STUDY
The report analyzes the Neurologic Disorders Therapeutics market by the following Segments, and Geographic Regions/Countries:
Segments:
Drug Class (Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class, Other Drug Classes); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies).
Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa..
SELECT PLAYERS
AstraZeneca PLC; Biogen, Inc.; Biohaven, Ltd.; Eisai Co., Ltd.; H. Lundbeck A/S; Ionis Pharmaceuticals, Inc.; Mitsubishi Tanabe Pharma Corporation; Neurelis, Inc.; Neurocrine Biosciences, Inc.; Neurona Therapeutics, Inc.; Ovid Therapeutics, Inc.; Pfizer, Inc.; Sanofi SA; UCB SA; Voyager Therapeutics, Inc.
TABLE OF CONTENTS
I. METHODOLOGY |
II. EXECUTIVE SUMMARY |
1. MARKET OVERVIEW |
Influencer Market Insights |
World Market Trajectories |
Global Economic Update |
Neurologic Disorders Therapeutics – Global Key Competitors Percentage Market Share in 2024 (E) |
Competitive Market Presence - Strong/Active/Niche/Trivial for 86 Players Worldwide in 2024 (E) |
2. FOCUS ON SELECT PLAYERS |
3. MARKET TRENDS & DRIVERS |
Rising Prevalence of Neurologic Disorders Drives Demand for Therapeutics |
Advancements in Neurotherapeutics Propel Market Growth |
Growing Awareness of Neurologic Health Expands Addressable Market Opportunity |
Development of Precision Medicine and Targeted Therapies Strengthens Business Case |
Innovations in Neurostimulation and Neuromodulation Therapies Generate Market Interest |
Development of Regenerative Medicine and Stem Cell Therapies Propels Market Growth |
4. GLOBAL MARKET PERSPECTIVE |
World Neurologic Disorders Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030 |
World Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR |
World Historic Review for Neurologic Disorders Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
World 15-Year Perspective for Neurologic Disorders Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030 |
World Recent Past, Current & Future Analysis for Anticholinergic Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR |
World Historic Review for Anticholinergic Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
World 15-Year Perspective for Anticholinergic Drug Class by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030 |
World Recent Past, Current & Future Analysis for Analgesics Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR |
World Historic Review for Analgesics Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
World 15-Year Perspective for Analgesics Drug Class by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030 |
World Recent Past, Current & Future Analysis for Antiepileptic Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR |
World Historic Review for Antiepileptic Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
World 15-Year Perspective for Antiepileptic Drug Class by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030 |
World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR |
World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
World 15-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030 |
World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR |
World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030 |
World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR |
World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
World 15-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030 |
World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR |
World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
World 15-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030 |
III. MARKET ANALYSIS |
UNITED STATES |
Neurologic Disorders Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E) |
USA Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
USA Historic Review for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
USA 15-Year Perspective for Neurologic Disorders Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030 |
USA Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
USA Historic Review for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
USA 15-Year Perspective for Neurologic Disorders Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030 |
CANADA |
Canada Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
Canada Historic Review for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
Canada 15-Year Perspective for Neurologic Disorders Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030 |
Canada Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
Canada Historic Review for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
Canada 15-Year Perspective for Neurologic Disorders Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030 |
JAPAN |
Neurologic Disorders Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E) |
Japan Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
Japan Historic Review for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
Japan 15-Year Perspective for Neurologic Disorders Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030 |
Japan Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
Japan Historic Review for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
Japan 15-Year Perspective for Neurologic Disorders Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030 |
CHINA |
Neurologic Disorders Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E) |
China Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
China Historic Review for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
China 15-Year Perspective for Neurologic Disorders Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030 |
China Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
China Historic Review for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
China 15-Year Perspective for Neurologic Disorders Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030 |
EUROPE |
Neurologic Disorders Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E) |
Europe Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR |
Europe Historic Review for Neurologic Disorders Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
Europe 15-Year Perspective for Neurologic Disorders Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030 |
Europe Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
Europe Historic Review for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
Europe 15-Year Perspective for Neurologic Disorders Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030 |
Europe Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
Europe Historic Review for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
Europe 15-Year Perspective for Neurologic Disorders Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030 |
FRANCE |
Neurologic Disorders Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E) |
France Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
France Historic Review for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
France 15-Year Perspective for Neurologic Disorders Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030 |
France Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
France Historic Review for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
France 15-Year Perspective for Neurologic Disorders Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030 |
GERMANY |
Neurologic Disorders Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E) |
Germany Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
Germany Historic Review for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
Germany 15-Year Perspective for Neurologic Disorders Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030 |
Germany Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
Germany Historic Review for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
Germany 15-Year Perspective for Neurologic Disorders Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030 |
ITALY |
Italy Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
Italy Historic Review for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
Italy 15-Year Perspective for Neurologic Disorders Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030 |
Italy Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
Italy Historic Review for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
Italy 15-Year Perspective for Neurologic Disorders Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030 |
UNITED KINGDOM |
Neurologic Disorders Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E) |
UK Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
UK Historic Review for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
UK 15-Year Perspective for Neurologic Disorders Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030 |
UK Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
UK Historic Review for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
UK 15-Year Perspective for Neurologic Disorders Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030 |
SPAIN |
Spain Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
Spain Historic Review for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
Spain 15-Year Perspective for Neurologic Disorders Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030 |
Spain Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
Spain Historic Review for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
Spain 15-Year Perspective for Neurologic Disorders Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030 |
RUSSIA |
Russia Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
Russia Historic Review for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
Russia 15-Year Perspective for Neurologic Disorders Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030 |
Russia Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
Russia Historic Review for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
Russia 15-Year Perspective for Neurologic Disorders Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030 |
REST OF EUROPE |
Rest of Europe Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
Rest of Europe Historic Review for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
Rest of Europe 15-Year Perspective for Neurologic Disorders Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030 |
Rest of Europe Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
Rest of Europe Historic Review for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
Rest of Europe 15-Year Perspective for Neurologic Disorders Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030 |
ASIA-PACIFIC |
Neurologic Disorders Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E) |
Asia-Pacific Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR |
Asia-Pacific Historic Review for Neurologic Disorders Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
Asia-Pacific 15-Year Perspective for Neurologic Disorders Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030 |
Asia-Pacific Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
Asia-Pacific Historic Review for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
Asia-Pacific 15-Year Perspective for Neurologic Disorders Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030 |
Asia-Pacific Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
Asia-Pacific Historic Review for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
Asia-Pacific 15-Year Perspective for Neurologic Disorders Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030 |
AUSTRALIA |
Neurologic Disorders Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E) |
Australia Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
Australia Historic Review for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
Australia 15-Year Perspective for Neurologic Disorders Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030 |
Australia Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
Australia Historic Review for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
Australia 15-Year Perspective for Neurologic Disorders Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030 |
INDIA |
Neurologic Disorders Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E) |
India Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
India Historic Review for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
India 15-Year Perspective for Neurologic Disorders Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030 |
India Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
India Historic Review for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
India 15-Year Perspective for Neurologic Disorders Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030 |
SOUTH KOREA |
South Korea Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
South Korea Historic Review for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
South Korea 15-Year Perspective for Neurologic Disorders Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030 |
South Korea Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
South Korea Historic Review for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
South Korea 15-Year Perspective for Neurologic Disorders Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030 |
REST OF ASIA-PACIFIC |
Rest of Asia-Pacific Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
Rest of Asia-Pacific Historic Review for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
Rest of Asia-Pacific 15-Year Perspective for Neurologic Disorders Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030 |
Rest of Asia-Pacific Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
Rest of Asia-Pacific Historic Review for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
Rest of Asia-Pacific 15-Year Perspective for Neurologic Disorders Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030 |
LATIN AMERICA |
Neurologic Disorders Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E) |
Latin America Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR |
Latin America Historic Review for Neurologic Disorders Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
Latin America 15-Year Perspective for Neurologic Disorders Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030 |
Latin America Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
Latin America Historic Review for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
Latin America 15-Year Perspective for Neurologic Disorders Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030 |
Latin America Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
Latin America Historic Review for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
Latin America 15-Year Perspective for Neurologic Disorders Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030 |
ARGENTINA |
Argentina Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
Argentina Historic Review for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
Argentina 15-Year Perspective for Neurologic Disorders Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030 |
Argentina Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
Argentina Historic Review for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
Argentina 15-Year Perspective for Neurologic Disorders Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030 |
BRAZIL |
Brazil Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
Brazil Historic Review for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
Brazil 15-Year Perspective for Neurologic Disorders Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030 |
Brazil Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
Brazil Historic Review for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
Brazil 15-Year Perspective for Neurologic Disorders Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030 |
MEXICO |
Mexico Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
Mexico Historic Review for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
Mexico 15-Year Perspective for Neurologic Disorders Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030 |
Mexico Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
Mexico Historic Review for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
Mexico 15-Year Perspective for Neurologic Disorders Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030 |
REST OF LATIN AMERICA |
Rest of Latin America Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
Rest of Latin America Historic Review for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
Rest of Latin America 15-Year Perspective for Neurologic Disorders Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030 |
Rest of Latin America Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
Rest of Latin America Historic Review for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
Rest of Latin America 15-Year Perspective for Neurologic Disorders Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030 |
MIDDLE EAST |
Neurologic Disorders Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E) |
Middle East Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR |
Middle East Historic Review for Neurologic Disorders Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
Middle East 15-Year Perspective for Neurologic Disorders Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030 |
Middle East Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
Middle East Historic Review for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
Middle East 15-Year Perspective for Neurologic Disorders Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030 |
Middle East Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
Middle East Historic Review for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
Middle East 15-Year Perspective for Neurologic Disorders Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030 |
IRAN |
Iran Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
Iran Historic Review for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
Iran 15-Year Perspective for Neurologic Disorders Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030 |
Iran Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
Iran Historic Review for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
Iran 15-Year Perspective for Neurologic Disorders Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030 |
ISRAEL |
Israel Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
Israel Historic Review for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
Israel 15-Year Perspective for Neurologic Disorders Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030 |
Israel Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
Israel Historic Review for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
Israel 15-Year Perspective for Neurologic Disorders Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030 |
SAUDI ARABIA |
Saudi Arabia Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
Saudi Arabia Historic Review for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
Saudi Arabia 15-Year Perspective for Neurologic Disorders Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030 |
Saudi Arabia Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
Saudi Arabia Historic Review for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
Saudi Arabia 15-Year Perspective for Neurologic Disorders Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030 |
UNITED ARAB EMIRATES |
UAE Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
UAE Historic Review for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
UAE 15-Year Perspective for Neurologic Disorders Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030 |
UAE Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
UAE Historic Review for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
UAE 15-Year Perspective for Neurologic Disorders Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030 |
REST OF MIDDLE EAST |
Rest of Middle East Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
Rest of Middle East Historic Review for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
Rest of Middle East 15-Year Perspective for Neurologic Disorders Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030 |
Rest of Middle East Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
Rest of Middle East Historic Review for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
Rest of Middle East 15-Year Perspective for Neurologic Disorders Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030 |
AFRICA |
Neurologic Disorders Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E) |
Africa Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
Africa Historic Review for Neurologic Disorders Therapeutics by Drug Class - Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
Africa 15-Year Perspective for Neurologic Disorders Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anticholinergic Drug Class, Analgesics Drug Class, Antiepileptic Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030 |
Africa Recent Past, Current & Future Analysis for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
Africa Historic Review for Neurologic Disorders Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
Africa 15-Year Perspective for Neurologic Disorders Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030 |
IV. COMPETITION |
PREVIEW REPORT
Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.
What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com